Sarepta Therapeutics

Sarepta Therapeutics

Yahoo Finance • 3 days ago

Jim Cramer Makes a Contrarian Call on Chipotle (CMG)

On October 7, a caller asked whether Chipotle Mexican Grill, Inc. (NYSE:CMG) would reach lower lows before recovering. Mad Money host Jim Cramer replied: You know what? CMG, I still think Scott Boatwright's getting it right. But you know... Full story

Yahoo Finance • 3 days ago

Veeva Systems’ (VEEV) Comeback Gets Jim Cramer Talking

During the October 7 episode of Mad Money, Jim Cramer discussed Veeva Systems Inc. (NYSE:VEEV) as an example of a software business that had recovered from fears about AI disruption, as he said: Take Veeva Systems, the best of its busines... Full story

Yahoo Finance • 29 days ago

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

Company Logo Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Op... Full story

Yahoo Finance • last month

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

[Scientist use ai technology, biotechnology for Medical research and development of scientific lab. Medical Research Laboratory for Test and analysis chromosome DNA genetic.] Swiss drugmaker Novartis' (NVS [https://seekingalpha.com/symbol... Full story

Yahoo Finance • last month

Most shorted stocks on Wall Street

[short sale] abluecup As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% of shares outst... Full story

Yahoo Finance • 2 months ago

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Photo by geralt on Pixabay Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue. Moderna (MRNA) has returned about 486% over the trailing twelve months... Full story

Yahoo Finance • 2 months ago

Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome. Continue Reading... Full story

Yahoo Finance • 2 months ago

Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027

Earnings Call Insights: Sarepta Therapeutics (SRPT) Q2 2026 MANAGEMENT VIEW * “This is my first earnings call as CEO of Sarepta...” and “we have narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with a m... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

This article first appeared on GuruFocus. Net Loss: $194.3 million, or a loss of $1.36 per share, for the fiscal 2026 third quarter ended June 30, 2026. Revenue: Approximately $75 million for the quarter, up from $28 million in the prior... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics Names Michael Severino As CEO; Shares Rise In Pre-Market

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), a company focused on genetic medicine for rare diseases, has appointed Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino will also join the company's Board... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

– Severino joins Sarepta's Board of Directors – Doug Ingram to retire from Sarepta CAMBRIDGE, Mass., July 27, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, to... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

CAMBRIDGE, Mass., July 22, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes... Full story

Yahoo Finance • 3 months ago

2 Beaten-Down Stocks That Still Aren't Worth Buying

Buying shares of excellent companies that have fallen out of favor is a great way to earn superior returns over the long run. However, investors should be careful not to catch a falling knife. Corporations often fail to keep up with broade... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 30, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensatio... Full story

Yahoo Finance • 5 months ago

Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

DENVER, May 27, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations acros... Full story

Yahoo Finance • 5 months ago

My Top 3 Biotech Stocks for May 2026

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billio... Full story

Yahoo Finance • 5 months ago

Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock

Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the best gene therapy stocks to buy in 2026. Sarepta’s Q1 2026 report, released on May 6, showed that both earnings and revenue surpassed analysts’ expectations. Adjusted EPS of $3.16 smashe... Full story

Yahoo Finance • 5 months ago

Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.

Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown. Continue Reading... Full story

Yahoo Finance • 5 months ago

Sarepta (SRPT) Q1 2026 Earnings Transcript

Image source: The Motley Fool. Date Wednesday, May 6, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Douglas IngramPresident, Research and Development and Technical Operations — Louise Rodino-KlapacChief Commercial Of... Full story

Yahoo Finance • 5 months ago

Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?

Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this article, we will summarize the bulls’ thesis on PGEN. Precigen, Inc.'s share was trading at $4.0200 as of April 28... Full story